Transcode Therapeutics, Inc.
Transcode Therapeutics, Inc. (RNAZ): 6 pipeline candidates · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.4 months
D/E 10.10 · 0% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for Transcode Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.1M
Cash
$12.8M
Quarterly Burn
$5.0M
Runway
8.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| seviprotimut-l | Phase 3 |
| ttx-mc138 | Phase 1/Phase 2 |
| ttx-riga | Preclinical |
| ttx-simyc | Preclinical |
| ttx-sipdl1 | Preclinical |
| uio-524 | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$249K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 13,090 | $113K |
| geode capital management, llc | 12,740 | $110K |
| vanguard fiduciary trust co | 2,982 | $26K |
| wells fargo & company/mn | 55 | $474 |
| royal bank of canada | 8 | $0 |
Frequently asked questions
How many drug candidates are in Transcode Therapeutics, Inc.'s pipeline?
Transcode Therapeutics, Inc. (RNAZ) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Transcode Therapeutics, Inc.'s lead drug candidate?
Transcode Therapeutics, Inc.'s most advanced tracked candidate is seviprotimut-l (Phase 3) for Adjuvant treatment of patients with Stages IIB and IIC melanoma.
What is Transcode Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Transcode Therapeutics, Inc. has approximately 8.4 months of cash runway.
What is Transcode Therapeutics, Inc.'s market capitalization?
Transcode Therapeutics, Inc.'s market capitalization is approximately $5.1M.
Who is the CEO of Transcode Therapeutics, Inc.?
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. is the chief executive officer of Transcode Therapeutics, Inc. (RNAZ).
Get the full picture on Transcode Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.